Effect of neonatal BCG vaccination on the evolution of Hashimoto's Thyroiditis

- 3 Kanhaiya Agrawal, Preetam Basak, Darshan Badal, Pinaki Dutta, Rama Walia, Naresh
- 4 Sachdeva.

1

2

7

8

9

16

17

- 5 Department of Endocrinology, Post Graduate Institute of Medical Education and Research,
- 6 Chandigarh, India.

Corresponding Author:

- 10 Prof. Naresh Sachdeva
- 11 Department of Endocrinology
- Post Graduate Institute of Medical Education and Research (PGIMER)
- 13 Chandigarh, INDIA
- 14 Phone: +91-172-2755282, +91-8437508280
- 15 E mail: sachdeva.naresh@pgimer.edu.in

ABSTRACT

18

- 19 Background: Hashimoto's thyroiditis (HT) involves the autoimmune destruction of
- 20 thyrocytes with the presence of anti-thyroid peroxidase (TPO) and/or anti-thyroglobulin (TG)
- antibodies. In autoimmune diseases, an immunomodulatory role of Bacillus Calmette-Guerin
- 22 (BCG) vaccination has been reported with decreased autoantibody production and induction
- of regulatory T cells. We hypothesize that a decline in the efficacy of BCG might be
- 24 associated with the appearance of HT during adulthood.
- 25 **Methods:** Adult subjects with subclinical HT (HT-SCH) (n=39) and non-autoimmune
- subclinical hypothyroidism (NA-SCH) (n=25) were enrolled along with euthyroid healthy
- 27 controls (HC) (n=20). The BCG-specific immune responses were determined by the Mantoux
- test and BCG-induced in-vitro proliferation of peripheral blood mononuclear cells (PBMC).
- 29 Anti-thyroid cellular immune responses were assessed in subjects with human leukocyte
- antigen (HLA)-A*02 and HLA-A*24 alleles by determining the frequency of CD8+ T cells
- 31 recognizing major histocompatibility complex (MHC) dextramers (DMR) carrying TPO-
- 32 derived peptides, by flow cytometry.
- 33 **Results:** The HT-SCH group had a lower rate of Mantoux test reactivity (38.5%) as
- compared to NA-SCH (64%) and HC subjects (65%) (p=0.047). However, the BCG-induced
- in-vitro proliferation of PBMC was similar in HT-SCH, NA-SCH, and HC groups. Further,
- 36 the BCG-vaccinated SCH subjects had lower levels of thyroid stimulating hormone (TSH)
- 37 (p=0.026). Next, the SCH subjects had higher frequencies of peripheral DMR+ CD8+ T cells
- as compared to HC subjects (p=0.001). Interestingly, the frequency of peripheral DMR+
- 39 CD8+ T cells was significantly higher in HT-SCH than HC subjects (p=0.045). Finally, we
- observed a positive correlation between the frequency of DMR+CD8+ T cells and TSH levels
- 41 (r = +0.620, p=0.006).
- 42 **Conclusions:** Collectively, our results highlight a complex relationship of neonatal BCG
- 43 vaccination with the genesis of HT, via modulation of autoimmune responses directed
- 44 towards thyroid autoantigens.
- 45 **Keywords:** Subclinical hypothyroidism, Autoimmune thyroid disease, BCG vaccine,
- Thyroid peroxidase (TPO), Autoreactive CD8+ T cells.

Authors' Contributions

47

48

- 49 KA collected and processed all blood samples, performed all the experiments, managed the
- 50 patients, collected and interpreted the data, and wrote the manuscript. PB assisted in
- 51 performing the experiments. **DB** helped in FACS analysis and determination of TPO
- 52 peptides. PD and RW helped in design of study, recruited and supervised the patient
- 53 selection and management. NS conceptualized and designed the study, supervised the
- 54 experiments and edited the manuscript.

56	Abbreviation	ıs:
57	APC	Allophycocyanin
58	BCG	Bacillus Calmette–Guérin
59	CFSE	Carboxyfluorescein diacetate succinimidyl ester
60	DMR	Dextramer
61	7-AAD	7-aminoactinomycin D
62	FITC	Fluorescein isothiocyanate
63	FMO	fluorescence minus one
64	FNAC	Fine needle aspiration cytology
65	HC	Healthy control
66	HIV	Human immunodeficiency virus
67	HLA	Human leukocyte antigen
68	HT	Hashimoto's thyroiditis
69	IEDB	Immune epitope database
70	MHC	Major histocompatibility complex
71	MS	Multiple sclerosis
72	MTB	Mycobacterium tuberculosis
73	NA-SCH	Non-autoimmune subclinical hypothyroid
74	PBMC	Peripheral blood mononuclear cells
75	PCR	Polymerase chain reaction
76	PerCP	Peridinin-chlorophyll
77	PPD	Purified protein derivative
78	RPMI	Roswell Park Memorial Institute
79	SCH	Sub-clinical hypothyroidism
80	SD	Standard deviation
81	T1D	Type-1 diabetes
82	T3	Triiodothyronine
83	T4	Thyroxine
84	TG	Anti-thyroglobulin
85	TPO	Anti-thyroid peroxidase
86	Tregs	Regulatory T cells
87	TSH	Thyroid stimulating hormone
88	TU	Tuberculin units
89		

INTRODUCTION

- 91 Hashimoto's thyroiditis (HT) is an autoimmune disorder of the thyroid gland characterized by
- 92 lymphocytic infiltration and destruction of thyrocytes. The prevalence of HT varies from 5-
- 93 10% and is on the rise, with female preponderance and advancing age [1-4]. The initial
- 94 pathogenesis of HT involves underlying genetic susceptibility and an environmental trigger
- 95 like infection, stress, etc., and is seen commonly in iodine-sufficient areas [5]. Various genes
- 96 implicated in the pathogenesis of HT include human leucocyte antigen (HLA-DR3, HLA-A2,

- 97 HLA-A24), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), and protein tyrosine
- 98 phosphatase-22 (PTPN22), etc. [6,7]. Further, there is systemic interaction between T cells,
- 99 antigen-presenting cells (APCs), and thyroid cells [8,9]. The pathological changes in HT
- appear with lymphocytic infiltration causing gradual destruction of thyroid follicles, followed
- by the replacement of thyroid parenchyma with fibrous tissue labeled as atrophic thyroiditis
- 102 [10].
- 103 Bacillus Calmette Guérin (BCG) vaccine is administered during the neonatal stage in
- 104 countries where tuberculosis (TB) is endemic. BCG has a protective effect against
- disseminated TB and meningitis in children, however, in adults, the immunoprotection
- against pulmonary TB declines due to a gradual loss in its efficacy [11,12]. In addition, an
- immunomodulatory role of BCG associated with a decrease in autoantibodies, and induction
- of regulatory T cells (Tregs) has been suggested [13]. BCG has also been shown to halt the
- pathogenesis of other autoimmune diseases, type-1 diabetes (T1D) and multiple sclerosis
- 110 (MS) by promoting the apoptosis of activated CD4+ T cells [14-17]. Since HT is a
- manifestation that appears mainly in adulthood, it could be possible that loss of efficacy of
- BCG might be associated with the appearance of thyroiditis. In a previous report, the BCG
- vaccine did not prevent the pathogenic initiation of autoimmunity against thyroid-stimulating
- hormone Receptor (TSHR) but halted the progression to Graves' disease [18,19]. However,
- the exact mechanisms behind this immunomodulation are still elusive. To date, there is no
- definitive evidence in humans on the protective or therapeutic effects of BCG in HT. In this
- direction, our study is aimed to understand, whether, the onset of HT is associated with a
- 118 decline in the efficacy of BCG vaccination. Here, we assessed BCG-specific immune
- 119 responses in the context of anti-thyroid autoimmune responses in recently diagnosed
- subclinical HT in comparison to non-autoimmune subclinical hypothyroid (NA-SCH) and
- euthyroid healthy control (HC) subjects.
- This article was previously presented as a meeting abstract at the Annual Endocrine Society
- 123 Conference (Virtual), March 2021 (Session: Thyroid Autoimmunity, COVID-19 & Thyroid
- 124 Disease. Abstract Number: 7318).

126

127

MATERIALS AND METHODS

Research design and recruitment of subjects

- A total of 84 subjects, aged 18-60 years, presenting with sub-clinical hypothyroidism (SCH)
- 129 (n=64) and euthyroid normal healthy controls (HC) (n=20) attending departments of
- Endocrinology at the Post Graduate Institute of Medical Education and Research (PGIMER),
- 131 Chandigarh, India were enrolled from Oct 2019 to Jan 2021. The SCH subjects were further
- divided into Hashimoto's thyroiditis (HT-SCH) (n=39) and non-autoimmune (NA-SCH)
- 133 (n=25) groups based on the presence of anti-thyroid antibodies. After obtaining informed
- consent, subjects were screened for TSH, thyroxine (T4), triiodothyronine (T3), free T4, free
- T3, thyroglobulin (TG), anti-thyroperoxidase (anti-TPO), anti-thyroglobulin (anti-TG) and

- 136 TSH receptor antibody titers. The criterion for inclusion of SCH subjects was; TSH levels
- between 4.2-10.0 µIU/ml with normal fT4 levels. Subjects with prior levothyroxine
- treatment, symptomatic hypothyroidism, infertility, pregnancy or planning for pregnancy,
- immune deficiency, diabetes mellitus, human immunodeficiency virus (HIV) infection,
- 140 chronic steroid or immunosuppressant medication, concurrent or past chemotherapy or
- radiotherapy, active or past tuberculosis, malignancy, and hepatic, renal or cardiac failure
- were excluded. The study was approved by the institutional ethics committee.
- The persistence of the efficacy of BCG vaccination was measured primarily in terms of
- response to the Mantoux test, and secondly by the presence of a scar formed during primary
- vaccination (BCG scar). Each subject's arms and legs were examined for the presence of a
- BCG scar. For the Mantoux test, 0.1 ml of five tuberculin units (TU) of purified protein
- derivative (PPD) solution was injected intra-dermally on the volar surface of the upper third
- region of the forearm by an expert vaccinator in all subjects and examined after 48 hours for
- 149 induration.

151

162

168

Peripheral blood mononuclear cell (PBMC) isolation and in-vitro culture with BCG

- A total of 10⁶ PBMCs/ml labeled with carboxyfluorescein diacetate succinimidyl ester
- 153 (CFSE) (5 mM) were plated in triplicates in flat bottom 24-well tissue culture plates (BD-
- 154 Falcon, USA) in Roswell Park Memorial Institute medium (RPMI)-1640 medium
- supplemented with 0.1% penicillin, streptomycin, 10% fetal calf serum and stimulated with
- optimized concentration of 30μl BCG (2-8 x 10⁶ bacilli/ml) (Serum institute, India) or 2μl
- antiCD3, anti-CD28 DynabeadsTM (Invitrogen, USA) (positive control) or without any
- stimulant (negative control) for 96 h at 37 °C in 5% CO2 [20,21]. Post culture, the cells were
- 159 centrifuged at 200g for 10 minutes, acquired on a flow cytometer (FACS Lyric), and
- analyzed using FACS Suite (version 1.3) software (BD Biosciences, USA). At least 10000
- events were acquired and proliferation indices were calculated as described previously [22].

HLA typing of subjects

- DNA was extracted from a 1.0 ml buffy coat of blood samples using QIAampTM DNA Blood
- Mini Kit (Qiagen, Hiden, Germany). HLA typing of the recruited subjects was carried out by
- sequence-specific primers-polymerase chain reaction (PCR-SSP) method (Olerup,
- Stockholm, Sweden). The PCR products were resolved on a 2% agarose gel. HLA type was
- interpreted using the SCORETM software (Olerup, Stockholm, Sweden).

Dextramer synthesis and validation

- HLA class I alleles (A*02, A*24) were selected for the synthesis of peptide dextramers
- 170 (DMR) as these alleles have a higher affinity for auto-antigenic thyroid peptides and
- 171 contribute to the development of HT [6]. Two different allophycocyanin (APC) labeled
- 172 MHC-I DMRs loaded with 8-11mer TPO-derived peptides (A*0201/ALARWLPV,

- 173 A*2402/VFSTAARF) having the highest cumulative affinity, as determined by MHC-I
- 174 peptide binding prediction software, Bioinformatics and Molecular Analysis Section
- 175 (BIMAS), (Centre for Information Technology, NIH, USA), SYFPEITHI (Biomedical
- 176 Informatics, Heidelberg, Germany) and T cell Epitope Prediction Tool of Immune Epitope
- Database (IEDB) (La Jolla, CA) were custom synthesized (Immudex, Denmark).

Immunophenotyping and analysis of TPO-specific CD8+ T cells

- The frequencies of TPO-dextramer (DMR) recognizing CD8+ T cells were measured to
- assess the degree of cellular immune responses against the thyroid gland. After determining
- HLA-I type, a fresh sample of heparinized peripheral blood was obtained from 14 SCH and 4
- 182 HC subjects for immunophenotyping. PBMCs were isolated by density gradient
- centrifugation with Ficoll (Sigma, USA). After checking cell viability by 7-amino
- actinomycin D (7-AAD) exclusion, TPO-specific CD8+ T cells were stained by incubating 2
- $\times 10^6$ PBMCs with 10 µl of respective DMRs at room temperature in the dark for 10 min.
- Anti-CD3 peridinin-chlorophyll (PerCP), anti-CD8 Alexa-fluor 700, and anti-CD4
- 187 fluorescein isothiocyanate (FITC) antibodies were then added with 15 min incubation,
- followed by washing with FACSTM buffer (BD Biosciences, USA). The stained cells were
- acquired on a flow cytometer (FACS Lyric) and analyzed using FACS Suite (version 1.3)
- 190 software (BD Biosciences, USA). At least one million total events were acquired and a
- minimum of 500,000 T cells were analyzed. Gating was first performed on lymphocytes
- 192 followed by gating of CD3+ CD4+ CD8+ cells to exclude CD3- T cells, monocytes, NK
- 193 cells, and B cells. CD8+ T cells recognizing the DMRs were then gated and analyzed.
- 194 Relevant fluorescence minus one (FMO) tubes were used to set gates.

Statistical Analysis

178

195

207

- 196 Statistical analyses were performed using Statistical Package for The Social Sciences (SPSS
- 197 v22.0) (SPSS Inc., Chicago, IL). Continuous variable data was expressed as mean± Standard
- 198 Deviation (SD) or median with inter-quartile range (1st 3rd) and discrete variables as
- 199 proportions. The student's t-test or one-way analysis of variance (ANOVA) was used to
- 200 compare the difference between means of normally distributed variables, while Mann
- Whitney or Kruskal Wallis was used to compare the difference between means of variable
- 202 with inequality of variance. The chi-square test or Fischer exact was used to examine the
- 203 difference between proportions. Comparison between the three groups was done using Tukey
- 204 post hoc analysis. The Pearson correlation coefficient was used for the correlation of
- 205 parametric data, whereas Spearman correlation analysis was performed for non-parametric
- data. All comparisons were done at a level of significance of 0.05.

RESULTS

Clinical characteristics of the study subjects

Of the total 64 subclinical hypothyroid subjects, 39 subjects had subclinical Hashimoto's thyroiditis (HT-SCH), 25 subjects had non-autoimmune SCH (NA-SCH) and 20 subjects were non-autoimmune euthyroid healthy controls (HC). The clinical and biochemical characteristics including TSH, T4, T3, fT4, and fT3 are documented in Table 1. The thyroid profile was repeated for all subjects at 6 months as a part of regular work-up and the intrasubject thyroid profile and anti-thyroid antibody status was similar at both time points. Other biochemical characteristics of the subjects are shown in Table 2.

Table 1: Clinical and biochemical characteristics of HT-SCH, NA-SCH and HC subjects.

HT-SCH (n=39)	NA-SCH (n=25)	HC (n=20)	P-value
37.64±11.5	34.92 ±10.3	33.5±8.02	0.313
33 (84.6)	16 (64)	16 (80)	0.149
25.8±4.65	25.4±7.09	25.66±3.20	0.944
34 (87.18)	19 (76)	19 (95)	0.182
7.0±1.7	6.8±1.51	2.3±0.66	0.001+
1.34±0.35	1.43±0.41	1.22±0.33	0.124
5.39±0.94	5.87±1.15	5.45±0.42	0.159
72.5 (11.7-59.6)	5 (5-9.8)	5 (5-9.0)	0.001++
294.6 (120.2-	`	10 (10-14.3)	0.001++
	37.64±11.5 33 (84.6) 25.8±4.65 34 (87.18) 7.0±1.7 1.34±0.35 5.39±0.94 72.5 (11.7-59.6)	37.64±11.5 34.92±10.3 33 (84.6) 16 (64) 25.8±4.65 25.4±7.09 34 (87.18) 19 (76) 7.0±1.7 6.8±1.51 1.34±0.35 1.43±0.41 5.39±0.94 5.87±1.15 72.5 (11.7-59.6) 5 (5-9.8) 294.6 (120.2- 26.4 (14.1-	37.64±11.5 34.92±10.3 33.5±8.02 33 (84.6) 16 (64) 16 (80) 25.8±4.65 25.4±7.09 25.66±3.20 34 (87.18) 19 (76) 19 (95) 7.0±1.7 6.8±1.51 2.3±0.66 1.34±0.35 1.43±0.41 1.22±0.33 5.39±0.94 5.87±1.15 5.45±0.42 72.5 (11.7-59.6) 5 (5-9.8) 5 (5-9.0) 294.6 (120.2- 26.4 (14.1- 10 (10-14.3)

^{*} Mean (±SD), P-value was calculated by one-way ANOVA test for parametric data, # Median (1st - 3rd quartile), P-value was calculated by Kruskal Wallis test for continuous non-parametric data and Chi-square test for categorical data. Abbreviations: HT-SCH Subclinical Hashimoto's thyroiditis, NA-SCH: Non-autoimmune subclinical hypothyroidism, HC: Healthy control, BMI: Body mass index, BCG: Bacillus Calmette-Guerin, TSH: Thyroid stimulating hormone, fT4: Free thyroxine, fT3: Free triiodothyronine, TG: Thyroglobulin, TPO: Thyroid peroxidase, Ab: Antibody; (+) p-value between HT-SCH and NA-SCH vs. HC, (++) p-value between HT-SCH vs. HC and NA-SCH subjects

Table 2: Other biochemical characteristics of HT-SCH, NA-SCH and HC subjects

Variables	HT-SCH (n=39)	NA-SCH (n = 25)	HC (n = 20)	P-value
Family History of Hypothyroidism, Present, n (%)	12 (31%)	4 (16%)	5 (25%)	0.390
Thyroglobulin (ng/ml)	8.95 (1.7- 43.22)	16.65 (7.63- 25.0)	16.7 (11.5- 22.1)	0.413
CRP (mg/L) # (Normal= 0-6)	2.44 (0.87-5.2)	3.12 (1.9-5.6)	3.1 (1-5.5)	0.810
Vitamin B12 (pg./ml)#	219.7 (144- 360)	215 (125.8-391)	256 (155-449)	0.638
Iron deficiency, n (%)	16 (41%)	10 (40%)	6 (28.6%)	0.653
Vitamin D (ng/ml)#	15.7 (9.9-22.9)	16.23 (10-24.7)	12 (7-20.1)	0.328
Total cholesterol (mg/dl)*	169.13±27.45	174.97±41.36	150.46±27.13	0.043+
LDL (mg/dl)*	106.61±24.67	109.38±36.40	88.94±25.56	0.056
HDL (mg/dl)*	45.43±11.91	51.07±9.26	45.03±8.84	0.234
Triglyceride (mg/dl)*	129.13±63.93	116.82±56.53	124.21±51.22	0.749
Hemoglobin (g/dl)*	12.24±1.30	12.35±1.9	12.49±1.37	0.819
Urea (mg/dl)*	20.64±6.36	21.86±5.46	18.64±6.8	0.157
Uric acid (mg/dl)*	4.44±1.09	4.69±1.07	3.69±1.3	0.705
Creatinine (mg/dl)*	0.74±0.24	0.74±0.15	0.68±0.19	0.467
Total protein (g/dl)*	7.52±0.44	7.55±0.57	7.53±0.52	0.979
Albumin (g/dl)*	4.46±0.33	4.51±0.41	4.33±0.37	0.174
Bilirubin (mg/dl)*	0.57±0.25	0.60±0.26	0.73±0.27	0.066
ALP (U/L) *	94.47±40.5	89.48±21.19	81.45±22.93	0.313
AST (U/L)*	27.35±7.48	25.97±14.69	27.6±8.8	0.852
ALT (U/L)*	28.53±14.63	31.90±27.59	27.65±17.51	0.723

^{*} Mean(±SD), P-value was calculated by one-way ANOVA test for parametric data, # Median (1st - 3rd quartile), P-value was calculated by Kruskal Wallis test for continuous non-parametric data, and Chi-square test for categorical data. (+) p-value between NA-SCH and HC subjects. Abbreviations: HT-SCH Subclinical Hashimoto's thyroiditis, NA-SCH: Non-autoimmune subclinical hypothyroidism, HC: Healthy control, CRP: C-reactive protein, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, ALP: Alkaline phosphatase, AST: aspartate aminotransferase, ALT: Alanine transaminase.

Assessment of efficacy of primary BCG vaccination

The efficacy of primary (neonatal) BCG vaccination was determined by Mantoux test reactivity and by in-vitro proliferative responses of peripheral blood lymphocytes to BCG. The Mantoux test-associated induration was observed in fewer HT-SCH subjects (induration diameter ≥ 5mm) (38.5%) as compared to NA-SCH (64%) and HC (65%) subjects (p=0.047) (Figure 1) (Table 3), with odds ratio (OR) between HT-SCH versus HC and NA-SCH subjects being, 0.34 (0.11-1.0, p=0.05) and 0.35 (0.12-0.99, p=0.046), respectively. Secondly, the peripheral blood mononuclear cells were isolated from the subjects and cultured in the presence of BCG vaccine (Figure 2). In contrast to the Mantoux test, the in-vitro lymphocyte proliferation in the presence of BCG was similar in HT-SCH and NA-SCH subjects (proliferation index, 2.55±0.31 vs. 2.51±0.41, p=0.889).

Figure 1: Representative image of induration at forearm, after 48 hours of Mantoux test.



Legend: An induration diameter < 5mm was considered as non-reactive.

Table 3: Mantoux test response and BCG-induced *in vitro* lymphocyte proliferation in HT-SCH, NA-SCH and HC subjects

Outcome variables		HT-SCH	NA-SCH	HC (n=20)	P-value
		(n=39)	(n=25)		
Mantoux	Positive, n (%)	15 (38.5)	16 (64)	13 (65)	0.047+

Test	Negative, n (%)	24 (61.5)	09 (36)	07 (35)	
Proliferation	index (BCG)*	2.55±0.31	2.51±0.41	2.46±0.29	0.667
Proliferation	index (anti-	2.59±0.26	2.53±0.39	2.44±0.26	0.285
CD3/CD28) *					
Proliferation	index (MC)*	2.51±0.28	2.44±0.38	2.40±0.27	0.677

^{*} Mean(±SD) p-value was calculated by independent-samples t-test for parametric data and chi-square test for categorical variables. (+) p-value between HT-SCH vs. NA-SCH and HC subjects. Abbreviations: HT-SCH: subclinical Hashimoto's thyroiditis, NA-SCH: non-autoimmune subclinical hypothyroidism, HC: healthy control, BCG: Bacillus Calmette-Guerin, CD: cluster of differentiation, MC: Media control.

258

259

260

261


262

263264

265

266

Figure 2: Representative flow-cytograms showing proliferation of CFSE labelled peripheral blood mononuclear cells (PBMC) isolated from the peripheral blood of a subject with subclinical Hashimoto's thyroiditis (HT-SCH).



Legend: The PBMCs were labeled with CFSE (5mM) at RT for 20 min then stimulated invitro with BCG or anti-CD3, anti-CD28 Dynabeads for 96 hours and analyzed on a flow

269

270

271272

273

274

275

276

277

278

279 280

281

282

283

284

285

286

287

288

289 290

291

292

293

294

295

296


297

298

299


cytometer. P2 represents the parent population, whereas P3-P8 represent the daughter population after consecutive divisions. a) Lymphocytes were gated as per forward and side scatter profiles. The proliferation of CFSE labeled lymphocytes in, b) unstimulated cultures (negative control, MC), (c), in the presence of anti-CD3, anti-CD28 DynabeadsTM (positive control), and (d), in the presence of BCG (30 µl/well). Assessment of autoimmune responses to thyroid antigens As a measure of humoral autoimmunity towards the thyroid gland, we assessed the titers of anti-TPO, anti-TG, and anti-TSHR antibodies in all subjects. Amongst the SCH group, anti-TPO, anti-TG, and both (anti-TPO and anti-TG) antibodies were positive in 64%, 77%, and 41% of subjects respectively. The levels of anti-TSHR antibodies were low and well below the cut-off limit (<0.8 IU/L) in all three groups, indicating the absence of humoral immune responses toward TSHR. To determine the HLA-specific cellular immune responses toward the thyroid gland, we performed HLA-typing of the subjects and chose TPO as the target antigen. At first, we observed heterogeneity of HLA-I alleles in our study subjects. HLA typing was performed in 52/84 subjects, including 41 SCH and 11 healthy controls. In the case of MHC-I, HLA-A*24 (41%) was the most frequent allele in SCH subjects followed by HLA-B*07 (37%) and HLA-A*01 (31%). HLA-A*02 was seen in 27% of subjects of SCH. In the case of MHC class II, the most frequent allele was HLA-DQB1*02 (78%) followed by HLA-DRB1*01 (65%) (Figure 3). Based on the frequency of HLA-I alleles, we assessed the frequency of peripheral CD8+ T cells that bind to TPO-derived epitopes using MHC-I dextramers. These autoreactive cells were termed DMR+ CD8+ T cells and analyzed by flow cytometry (Figure 4).

Figure 3: HLA alleles of the study subjects.



Legend: a: A representative agarose gel image of PCR amplified products during molecular HLA typing (PCR-SSP), showing the internal control band, amplified allele band and negative control. Lane 1 represents negative control. The amplified internal control is present in all the lanes except negative control. Amplified allele bands are observed in lanes 2, 5, 18, 38, 39, 55, 1, 62, 64, 65, 71, 80, 81, 82 and 86. HLA type of the subjects was determined using SCORETM software provided by the manufacturer (Olerup, Stockholm, Sweden). **b:** Frequency of various HLA I and HLA II alleles determined by molecular HLA typing in SCH subjects.

Figure 4: Representative images showing gating strategy for the immunophenotyping of TPO-specific autoreactive CD8+ T (DMR+ CD8+ T cells) cells in the peripheral blood from a HT-SCH subject.



Legend: a) Lymphocytes were gated as per forward and side scatter profiles, b) gating of CD3+ T cells, c) gating of CD8+CD4- T cells in FMO tube, d) DMR+CD8+ T cells set in FMO tube for negative control, e) gating of CD8+CD4- T cells and f) CD8+ T cells recognizing DMRs carrying TPO derived peptide selected as DMR+ve cells.

We took HLA-A*02 and HLA-A*24 negative HT-SCH subjects as negative controls to determine the frequency of DMR+CD8+ T cells in SCH subjects in comparison to HC subjects as described previously [20]. The average frequency (%) of DMR+CD8+ T cells was

- deducted from the frequency (%) of DMR+CD8+ T cells in HLA-A*02 and HLA-A*24
- positive subjects to calculate the actual frequency (%) of autoreactive CD8+ T cells
- 338 recognizing TPO epitopes. At first, to rule out whether the SCH subjects had higher
- frequency of peripheral CD8+ T cells, we calculated the CD4:CD8 T cell ratios and observed
- that HC and SCH subjects had similar CD4: CD8 T cell ratios (2.57±1.1 vs. 2.06±1.09,
- p=0.438), Interestingly, we observed that the SCH subjects had higher frequencies of DMR+
- 342 CD8+ T cells $(7.6\pm4.46\% \text{ vs. } 1.61\pm0.80\%, p=0.001)$ as compared to healthy controls.
- The calculated frequency (%) of DMR+ CD8+ T cells was found to be similar in NA-SCH
- and HT-SCH subjects [mean (±SD) 6.6±4.33% vs. 9.02±4.17%, p=0.737]. As expected, the
- DMR+ CD8+ T cells were significantly higher in HT-SCH than in HC subjects (9.02±4.17
- 346 vs. 1.61±0.80 %, p=0.045) (Table 4) (Figure 5).
- Next, we observed a significant positive correlation between the frequency of DMR+CD8+ T
- 348 cells and TSH levels (r=+0.620, p=0.006) in the complete cohort, indicating that the
- 349 appearance of TPO-specific CD8+ T cells is associated with the onset of hypothyroid disease.
- However, there was no significant correlation between the frequency of DMR+CD8+ T cells
- and anti-TPO antibody titers (r=+0.207, p=0.409) or anti-TG antibody titers (r=+0.108,
- 352 p=0.669).

355

356

357

359


Table 4: Cellular autoimmune responses to thyroid antigens in SCH and HC subjects


Outcome variables	HT-SCH	NA-SCH	HC (n= 04)	P-value
	(n=09)	(n=05)		
CD3+ Lymphocytes (%)*	60.28±8.53	68.12±3.55	65.0±15.97	0.336
CD3+CD8+ T cells (%)*	18.47±7.32	21.67±6.43	21.17±14.90	0.723
CD3+CD4+ T cells (%)*	35.71±10.01	36.56±7.64	42.68±16.65	0.559
CD4: CD8 T cell ratio*	2.18±1.01	1.83±0.74	2.57±1.1	0.555
DMR +ve (CD8+ T cells) (%)*	9.02±4.17	6.6±4.33	1.61±0.80	0.045+

* Mean (±SD), P value was calculated by one-way ANOVA test. (+), p-value between HT-SCH vs. HC subjects. Abbreviations: HT-SCH: subclinical Hashimoto's thyroiditis, NA-SCH: non-autoimmune subclinical hypothyroidism, HC: healthy control, DMR: APC labelled MHC-I Dextramers loaded with thyroid peroxidase (TPO) derived peptide, BCG: Bacillus Calmette-

358 Guerin, CD: Cluster of differentiation.

Figure 5: Assessment of anti-thyroid autoreactive CD8+ T cell responses





Legend: a) Comparison of the mean relative frequency of DMR+ CD8+ T cells in the peripheral blood of subclinical hypothyroid (SCH) and healthy control (HC) subjects. b) Comparison of the mean relative frequency of DMR+CD8+ T cells in subclinical Hashimoto's thyroiditis (HT-SCH), non-autoimmune SCH (NA-SCH) subjects, and healthy controls (HC). c) Correlation between TSH levels and DMR+CD8+ T cells (amongst CD8+ T cells). Data is presented as mean \pm SD and Student's t-test was used to compare the means in figure (a) whereas, one-way ANOVA followed by Tukey's multiple comparison test was used to compare the means in figure (b), and correlation is presented as Pearson coefficient in figure (c). $P\Box < \Box 0.05$ was considered as statistically significant.

Comparison of SCH subjects based on BCG vaccination

The presence or absence of a scar at the site of BCG administration may suggest, whether the subject has been vaccinated (Table 5). Overall, the TSH levels were significantly lower in BCG-vaccinated subjects (presence of a BCG scar) $(6.75\pm1.56 \text{ vs. } 7.94\pm1.67 \text{ } \mu\text{IU/ml}, p=0.026)$ as compared to non-BCG vaccinated subjects (absence of a BCG scar). The non-

BCG-vaccinated SCH subjects had a lower BMI (22.15±2.81 vs. 26.34±5.82, p=0.030) as compared to the BCG-vaccinated SCH subjects. Overall, the anti-mycobacterial response i.e., Mantoux test (induration in mm) was comparable in both the groups (p=0.663). Also, the non-BCG vaccinated SCH subjects had similar in-vitro BCG-induced lymphocyte proliferation response (2.38±0.29 vs. 2.56±0.36, p=0.127) as compared to the BCG vaccinated SCH subjects.

Table 5: Thyroid profile, anti-mycobacterial responses and BCG-induced *in-vitro* T cell proliferation in SCH subjects with or without BCG vaccination

Variables		BCG scar absent	BCG scar present	P-value
		(n = 11)	$(\mathbf{n}=53)$	
Age (years)*	•	31.92±7.75	36.20±11.14	0.118
BMI (kg/m ²))*	22.15±2.81	26.34±5.82	0.030
TSH (µIU/m	l)*	7.94±1.67	6.75±1.56	0.026
fT4(ng/dl)*		1.52±0.55	1.34±0.33	0.376
fT3(pmol/L)	*	5.74±0.92	5.53±1.07	0.468
Anti –TPO A	Ab (IU/ml)#	12.0 (5-150)	16.4 (5-75)	0.913
Anti - TG Al	b (IU/ml) [#]	56.0 (11-454)	106.9 (37.3-345.9)	0.516
Mantoux	Negative n (%)	5 (45.45)	28 (52.83)	0.663
Test	Positive n (%)	6 (54.55)	25 (47.17)	
Proliferation index (BCG)*		2.38±0.29	2.56±0.36	0.127

^{*} Mean(±SD), the p-value was calculated by independent-samples t-test for parametric variables. # Median (1st – 3rd quartile), the p-value was calculated by Mann Whitney U test for continuous non-parametric data and Chi-square test for categorical data. Abbreviations: BMI: Body mass index, BCG: Bacillus Calmette-Guerin, TSH: Thyroid stimulating hormone, fT4: Free thyroxine, fT3: Free triiodothyronine, TG: Thyroglobulin, TPO: Thyroid peroxidase, Ab: Antibody. The subjects with the presence of a BCG scar were considered as BCG vaccinated.

DISCUSSION

394

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

432

Hashimoto's thyroiditis is primarily mediated by autoreactive T cells that induce the destruction of thyrocytes. BCG vaccine has been shown to have an immunomodulatory role in autoimmune diseases like T1DM, and MS [15,16,23], however, to the best of our knowledge, there is no human study on the role of BCG vaccination in HT or related autoimmune thyroid diseases. We included only SCH subjects and attempted to assess the effects of prior BCG vaccination on anti-thyroid immune responses and its impact during the early pathogenesis of the disease

Overall, most of the HT-SCH subjects were non-reactive to the Mantoux test as compared to NA-SCH and HC subjects. Amongst the SCH subjects, the BCG-vaccinated group showed lower levels of TSH in comparison to the non-vaccinated group. Additionally, those SCH subjects retaining the efficacy of BCG had almost significantly lower titers of anti-TG antibodies. Together, these observations indicate that the persistence of BCG efficacy has some role in regulating autoimmune responses towards the thyroid gland. It is also pertinent to mention here that the BCG scar may be absent in 1-20 % of subjects even after vaccination [24,25]. There are a few reports where BCG vaccination has been shown to be associated with a lower frequency of autoreactive T cells resulting in a decrease in the pathogenesis of autoimmune diseases [14]. In the case of thyroid, in a mouse model of Graves' disease, Nagayama et al. (2004), demonstrated that BCG vaccination slows disease progression by diverting the anti-TSHR directed Th1 cells and reducing the production of anti-TSHR antibodies [19]. In another study, GAD65 and IA-2 autoantibody titers were observed to be lower in BCG-vaccinated (ascertained by the presence of a BCG scar) T1D subjects [26]. Likewise, in our study, prior BCG vaccination was associated with lower levels of TSH in SCH subjects.

418 In contrast to Mantoux reactivity, we did not find any difference between in-vitro BCG-419 induced PBMC proliferation in subjects in the context of their BCG vaccination status. We 420 think that there could be inherent potential differences between in-vivo and in-vitro responses 421 of T cells to BCG and this assay might not ascertain BCG vaccination efficacy, efficiently, 422 particularly in the Indian subcontinent due to the likelihood of prior exposure to 423 subclinical/environmental tuberculosis, non-tubercular infections. The absence of correlation 424 between in-vivo and in-vitro BCG-specific immune responses has been seen in similar 425 studies as well. Biswas et al. 1997 observed no correlation between Mantoux response and 426 PPD-induced lymphocyte proliferation in Eales' disease [27]. In another study, Arya et al. 427 (2018) observed that both healthcare workers and active tuberculosis patients had similar lymphocyte proliferation in response to Mycobacterium tuberculosis (MTB) Memory antigen 428 429 irrespective of their Mantoux test reactivity [28]. These findings suggest that 430 subclinical/environmental exposure to MTB in areas with a prevalence of tuberculosis 431 influences BCG-associated immune responses.

To study autoreactive T cells, various TPO peptides have been used previously [20]. We

could demonstrate peripheral autoreactive CD8+ T cells recognizing, TPO-derived peptides

- in both HT-SCH and NA-SCH subjects. The presence of autoreactive CD8+ T cells in NA-
- SCH could be attributed to higher levels of TSH, and without studying their phenotype it
- would be too early to label these DMR+CD8+ T cells as pathogenic. A similar study reported
- the presence of autoreactive CD8+ T cells recognizing TG and TPO epitopes in anti-TG and
- anti-TPO antibody-negative subjects [21]. Therefore, these observations support the
- occurrence of positive cellular immune responses even in the absence of humoral immune
- responses toward thyroid antigens [20,21]. However, we cannot comment on whether this
- could be attributed to the 'trained immunity' imparted by BCG, since we did not assess BCG
- reactive T cells in these subjects.
- 443 Another relevant finding from our study was a positive correlation between TSH levels and
- autoreactive CD8+T cells suggesting initiation of cellular autoimmunity leading to thyroid
- parenchymal destruction before the onset of humoral responses. Similarly, Ehlers et al.
- 446 (2012) showed a lack of correlation between anti-TPO Ab and autoreactive CD8+ T cells
- 447 [20]. This varying correlation of anti-thyroid antibodies with autoreactive CD8+ T cells
- probably highlights the fact that autoreactive CD8+ T cells emerge earlier than the
- 449 autoantibody-producing B cells, which likely have a bystander or a surrogate role rather than
- being pathogenic [6,10,29]. Since cytotoxic CD8+ T cells primarily mediate damage to the
- 451 thyroid gland, their appearance in both HT-SCH and NA-SCH subjects is an indication that
- 452 the onset of hypothyroidism perhaps also initiates a phase of autoimmunity. However, a
- smaller number of subjects available in the non-BCG vaccinated group, lack of objective
- evidence of iodine sufficiency, and fine needle aspiration cytology (FNAC) of the thyroid
- gland to confirm the diagnosis of autoimmunity are the main limiting factors in our study.
- Nevertheless, this is the first human study ever done in HT subjects highlighting the
- association between appearances of anti-thyroid autoimmunity in the context of BCG
- 458 vaccination.

469

Conclusions

- 460 In conclusion, our study highlighted a complex relationship between neonatal BCG
- 461 vaccination and the appearance of autoimmunity in the thyroid gland in SCH subjects. Our
- 462 results suggest that BCG vaccination has some influence on the genesis of HT by altering the
- 463 frequencies of autoreactive T cells and the appearance of antibodies directed toward thyroid
- 464 autoantigens. BCG is a time-tested safe vaccine that has already shown its non-specific
- effects in other infections and autoimmune diseases. We have now partially demonstrated
- 466 that neonatal BCG vaccination exerts an immunomodulatory role on thyroid autoimmunity.
- Our data warrants further long-term human studies in adult subjects with family history or
- early onset of HT to assess the utility of BCG in therapeutic vaccination.

Acknowledgements

- 470 We acknowledge the technical staff of the Department of Endocrinology, PGIMER,
- 471 Chandigarh, including Mr Vivek Sharma, Mudasir Hassen, Pintoo Kumar, Raj Davinder

- 472 Kaur for their support and assistance in performing all the laboratory investigations related to
- 473 this study.
- 474 Funding

- 475 This research did not receive any specific grant from any funding agency in public,
- 476 commercial or not-for-profit sector.
- 477 Conflict of Interest
- 478 All the authors declare that they have no conflict of interest.

480 REFERENCES

- 481 1. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P: Autoimmune thyroid
- disorders. Autoimmun Rev. 2015, 14:174–80. 10.1016/j.autrev.2014.10.016
- 483 2. McLeod DSA, Cooper DS: The incidence and prevalence of thyroid autoimmunity.
- 484 Endocrine. 2012, 42:252–65. 10.1007/s12020-012-9703-2
- 485 3. Deshmukh V, Behl A, Iyer V, Joshi H, Dholye JP, Varthakavi PK: Prevalence, clinical and
- biochemical profile of subclinical hypothyroidism in normal population in Mumbai.
- 487 Indian J Endocrinol Metab. 2013, 17:454–9. 10.4103/2230-8210.111641
- 488 4. Unnikrishnan A, Bantwal G, John M, Kalra S, Sahay R, Tewari N: Prevalence of
- 489 hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J
- 490 Endocrinol Metab. 2013, 17:647. 10.4103/2230-8210.113755
- 491 5. Nyström E, Berg GEB, Jansson SKG, Tørring O, Valdemarsson SV: Thyroid Disease in
- 492 Adults. Springer Berlin Heidelberg: Berlin, Heidelberg; 2011. 10.1007/978-3-642-13262-
- 493
- 494 6. Zaletel K, Gaberšček S: Hashimoto's Thyroiditis: From Genes to the Disease. Curr
- 495 Genomics. 2011, 12:576–88. 10.2174/138920211798120763
- 496 7. Frommer L, Kahaly GJ: Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic
- 497 Link. Front Endocrinol. 2021, 12:618213. 10.3389/fendo.2021.618213
- 498 8. Luty J, Ruckemann-Dziurdzińska K, Witkowski JM, Bryl E: Immunological aspects of
- autoimmune thyroid disease Complex interplay between cells and cytokines. Cytokine.
- 500 2019, 116:128–33. 10.1016/j.cyto.2019.01.003
- 9. Li Q, Wang B, Mu K, Zhang J: The pathogenesis of thyroid autoimmune diseases: New T
- lymphocytes Cytokines circuits beyond the Th1-Th2 paradigm. J Cell Physiol. 2019,
- 503 234:2204–16. 10.1002/jcp.27180

- 10. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ: Williams textbook of endocrinology. 14th ed. Elsevier, Inc: Philadelphia; 2019.
- 11. World Health Organization: BCG vaccine. WHO position paper. Releve Epidemiol Hebd. 2004, 79:27–38.
- 12. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F:
 Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published
- 510 literature. JAMA. 1994, 271:698-702.
- 13. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN: Impairment of Regulatory T-Cell
- Function in Autoimmune Thyroid Disease. Thyroid. 2013, 23:871–8.
- 513 10.1089/thy.2012.0514
- 14. Faustman DL, Wang L, Okubo Y, et al.: Proof-of-Concept, Randomized, Controlled
- 515 Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes.
- 516 PLoS ONE. 2012, 7:e41756. 10.1371/journal.pone.0041756
- 15. Kühtreiber WM, Tran L, Kim T, et al.: Long-term reduction in hyperglycemia in advanced
- type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. Npj
- 519 Vaccines. 2018, 3:. 10.1038/s41541-018-0062-8
- 16. Ristori G, Faustman D, Matarese G, Romano S, Salvetti M: Bridging the gap between
- 521 vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases
- of type 1 diabetes and multiple sclerosis. Curr Opin Immunol. 2018, 55:89–96.
- 523 10.1016/j.coi.2018.09.016
- 524 17. Dias HF, Kühtreiber WM, Nelson KJ, Ng NC, Zheng H, Faustman DL: Epigenetic changes
- related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for
- 526 KDM2B. Vaccine. 2021, S0264410X21004461. 10.1016/j.vaccine.2021.04.011
- 527 18. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B: Schistosoma mansoni
- 528 and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a
- 529 mouse model of Graves' hyperthyroidism. J Immunol Baltim Md 1950. 2004, 173:2167-
- 530 73.
- 531 19. Nagayama Y, McLachlan SM, Rapoport B, Oishi K: Graves' hyperthyroidism and the
- 532 hygiene hypothesis in a mouse model. Endocrinology. 2004, 145:5075–9.
- 533 10.1210/en.2004-0683
- 20. Ehlers M, Thiel A, Bernecker C, et al.: Evidence of a Combined Cytotoxic Thyroglobulin
- 535 and Thyroperoxidase Epitope-Specific Cellular Immunity in Hashimoto's Thyroiditis. J
- 536 Clin Endocrinol Metab. 2012, 97:1347–54. 10.1210/jc.2011-2178
- 537 21. Cai Y, Xu X, Zhang Z, et al.: Identification of novel HLA-A0201-restricted T-cell epitopes
- against thyroid antigens in autoimmune thyroid diseases. Endocrine. Published Online
- 539 First: 20 March 2020. 10.1007/s12020-020-02264-x

540 22. McMurchy AN, Levings MK: Suppression assays with human T regulatory cells: A technical guide: Highlights. Eur J Immunol. 2012, 42:27-34. 10.1002/eji.201141651 541 542 23. Kowalewicz-Kulbat M, Locht C: BCG and protection against inflammatory and autoimmune diseases. Expert Rev Vaccines. 2017, 16:699-708. 543 544 10.1080/14760584.2017.1333906 545 24. Dhanawade SS, Kumbhar SG, Gore AD, Patil VN: Scar formation and tuberculin 546 conversion following BCG vaccination in infants: A prospective cohort study. J Fam Med 547 Prim Care. 2015, 4:384-7. 10.4103/2249-4863.161327 548 25. Rani SH, Vijayalakshmi V, Sunil K, Lakshmi KA, Suman LG, Murthy KJ: Cell mediated 549 immunity in children with scar-failure following BCG vaccination. Indian Pediatr. 1998, 35:123-7. 550 551 26. Sanjeevi CB, Das AK, Shtauvere-Brameus A: BCG vaccination and GAD65 and IA-2 552 autoantibodies in autoimmune diabetes in southern India. Ann N Y Acad Sci. 2002, 553 958:293-6. 10.1111/j.1749-6632.2002.tb02990.x 554 27. Biswas J, Narain S, Roy S, Madhavan HN: Evaluation of lymphocyte proliferation assay to 555 purified protein derivative, enzyme linked immunosorbant assay, and tuberculin 556 hypersensitivity in Eales' disease. Indian J Ophthalmol. 1997, 45:93–7. 557 28. Arya S, Kumar SK, Nath A, Kapoor P, Aggarwal A, Misra R, Sinha S: Synergy between 558 tuberculin skin test and proliferative T cell responses to PPD or cell-membrane antigens 559 of Mycobacterium tuberculosis for detection of latent TB infection in a high disease-560 burden setting. PLOS ONE. 2018, 13:e0204429. 10.1371/journal.pone.0204429 561 29. Stassi G, De Maria R: Autoimmune thyroid disease: new models of cell death in 562 autoimmunity. Nat Rev Immunol. 2002, 2:195-204. 10.1038/nri750